Drug intelligence / Profile preview

MI-3

Development stage: Unknown
Modality: Small Molecules
Administration: In Vitro, Ex Vivo, Preclinical Animal Studies

Overview

MI-3 is a **potent inhibitor of the menin-MLL (mixed-lineage leukemia) interaction**. It demonstrates high affinity for this interaction, with an IC50 of 648 nM and a Kd of 201 nM. Menin is a protein that interacts with the MLL fusion proteins found in certain types of leukemia. Disruption of this interaction has shown promise as a therapeutic strategy in MLL-rearranged leukemias and other epigenetic oncology contexts. MI-3 is primarily used in research settings for **epigenetic studies and cancer research** and is not approved for clinical use in humans[4][9].

Other names: Menin-MLL inhibitor 3

Targets

KMT2A-FP (Lysine methyltransferase 2A fusion protein (MLL fusion protein))MEN1 (Menin)

Beyond the preview

Go deeper on MI-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MI-3.

Explore the full profile